MDWD Company Profile and Key Details

MDWD has shown mixed momentum, losing -1.33% over the past week and -9.55% over the past quarter, though year-to-date performance is down -7.91%. Short-term trend indicators are bullishly aligned (SMA20 -0.58%, SMA50 -2.45%, SMA200 -5.74%). The stock’s 14-day RSI is 48.31 (neutral), while the ATR of 0.67 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.15% below its high and over 23.9% above its low. Average 10-day trading volume of 138.28 thousand shares is significantly above the 3-month average of 86.85 thousand, indicating heightened recent market interest.

MediWound Ltd. has 12.91 million shares outstanding. The public float is 8.87 million shares, elevated short interest at 14.34% of float. This equals 1.61 million shares. The short ratio is 22.18 days. Institutional investors hold 66.16% of the float. Insiders own 15.88%. SHAMIR NACHUM holds 49.99 thousand shares, Fox David Morton has 20.48 thousand shares and Hess Shmuel has 0.00 shares. Over the past six months, insider transactions show balanced activity. They sold 4.37 thousand shares across 3 transactions.

Wall Street analysts project EPS growth of 7.32% annually over the next five years. The latest quarter delivered EPS of -$0.77. The next quarter is forecast at -$0.65. Next year's EPS is expected at -$66.87. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 2 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $36.00 to $32.00. The high target offers 160.12% upside. The low target suggests 131.21% downside. The mean target is $34.67. This offers 150.51% upside. MediWound Ltd. earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by 1.09%. The prior quarter beat by -64.62%. Over the last six quarters, Apple has recorded several small beats. These include -89.23% in May 21, 2025.

MediWound Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$7.24. This means the shares are trading below this model’s fair value.

MediWound Ltd. (NASDAQ:MDWD) closed at $13.84 USD, gaining $0.40 (2.98%) from the previous close of $13.44. The stock is currently mid-range between its 52-week high and low $12.52 and $20.30. With a market capitalization of about $177.78 million, MediWound Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.14). Key stats such as the average daily volume over the past year has been around 84.70 thousand shares, trading with heavier-than-usual volume. Headquartered in Yavne, HM, MediWound Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Ofer Gonen, the company employs approximately 121 people and listed since March 20, 2014. MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally.

Our AI price prediction model suggests that MediWound Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.75%, with price expected at $13.46 by September 22, 2026, within a range of $13.16 to $13.74 3-Month Outlook: Projected rise of 33.45%, reaching $18.47 by December 07, 2026, with a range of $17.14 to $19.48. 1-Year Outlook: Projected loss of -35.26%, with price at $8.96 by September 08, 2027, within a range of $4.90 to $9.97.

MediWound Ltd. (NASDAQ:MDWD) shares are flat -7.91% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows MediWound Ltd. trading at a premium to the broader market with a P/E of -8.68. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $27.85, suggesting 101.23% upside. Our AI forecast model points to short-term weakness (-2.75% over two weeks), a medium-term rise (33.45% over three months), and a longer-term loss (-35.26% over one year), with expected trading ranges indicating moderate volatility.

MediWound Ltd. trades at a P/E ratio of -8.68, slightly below the S&P 500 average, with a price-to-sales ratio of 15.05 and a price-to-book ratio of 5.02 trading at moderately above to book value. The P/FCF stands at -6.29, also below market averages.